November 2026
1. KAYSER S, Nagler A, Ferhat AT, Sanz J, et al
   Correction: T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: a study fro
   Bone Marrow Transplant. 2026 Nov 5. doi: 10.1038/s41409-026-03072.
   

   >> Share

   
   October 2026
2. DUQUE-AFONSO J, Finke J, Ferhat AT, Galimard JE, et al
   Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study
   Bone Marrow Transplant. 2026 Oct 23. doi: 10.1038/s41409-026-03073.
   

   >> Share

   
   
3. ZHANG X, Feng D, Cao Y, Xu M, et al
   The prognostic impact of CEBPA mutation in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
   Bone Marrow Transplant. 2026 Oct 16. doi: 10.1038/s41409-026-03068.
   

   >> Share

   
   
4. RUGGIU M, Gournay V, Labussiere H, Carre M, et al
   Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes.
   Bone Marrow Transplant. 2026 Oct 6. doi: 10.1038/s41409-026-03065.
   

   >> Share

   
   September 2026
5. CAMARILLAS S, Alonso-Saladrigues A, Navarro V, Marsal J, et al
   Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.
   Bone Marrow Transplant. 2026 Sep 29. doi: 10.1038/s41409-026-03057.
   

   >> Share

   
   
6. DUQUE-AFONSO J, Finke J, Ferhat-Berland T, Galimard JE, et al
   Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of
   Bone Marrow Transplant. 2026 Sep 10. doi: 10.1038/s41409-026-03016.
   

   >> Share

   
   
7. NAGLER A, Swoboda R, Ferhat AT, Blaise D, et al
   Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.
   Bone Marrow Transplant. 2026 Sep 2. doi: 10.1038/s41409-026-03012.
   

   >> Share

   
   
8. BERTON G, Furst S, Bouchacourt B, Harbi S, et al
   Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients.
   Bone Marrow Transplant. 2026;61:1188-1195.
   

   >> Share

   
   August 2026
9. NAGLER A, Esteve J, Galimard JE, Wu D, et al
   Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
   Bone Marrow Transplant. 2026 Aug 31. doi: 10.1038/s41409-026-03022.
   

   >> Share

   
   
10. GUILLERAULT L, Saultier P, Domenech C, Ducassou S, et al
    Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia.
    Bone Marrow Transplant. 2026 Aug 31. doi: 10.1038/s41409-026-03019.
    

    >> Share

    
    
11. WALKER I, Deotare U, Elemary M, Elsawy M, et al
    A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study
    Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03024.
    

    >> Share

    
    
12. NEVEN Q, Berbis J, Michel G, Domenech C, et al
    Long-term complications after total body irradiation in children younger than 4 years transplanted for acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2026 Aug 20. doi: 10.1038/s41409-026-03014.
    

    >> Share

    
    
13. SARACENI F, Angelucci E, Arpinati M, Bacigalupo A, et al
    Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).
    Bone Marrow Transplant. 2026 Aug 5. doi: 10.1038/s41409-026-02989.
    

    >> Share

    
    July 2026
14. WIRK B, McCarty J
    Are all mismatched donors the same in allogeneic hematopoietic cell transplantation for secondary acute myeloid leukemia in the posttransplant cyclophosphamide era?
    Bone Marrow Transplant. 2026 Jul 24. doi: 10.1038/s41409-026-02996.
    

    >> Share

    
    
15. CARTA R, De Luca CD, Bertaina V, Gaspari S, et al
    Efficacy of blinatumomab for dermatomyositis/SLE overlap syndrome occurring after allogeneic hematopoietic stem cell transplant performed for acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2026 Jul 21. doi: 10.1038/s41409-026-02990.
    

    >> Share

    
    
16. BALEYDIER F, Galimard JE, Bernard F, Gonzales F, et al
    Is the adult EBMT risk score valid and relevant for hematopoietic stem cell transplantation in children acute leukemia?
    Bone Marrow Transplant. 2026 Jul 20. doi: 10.1038/s41409-026-02952.
    

    >> Share

    
    
17. MAFFINI E, Labopin M, Raiola AM, Blaise D, et al
    Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society
    Bone Marrow Transplant. 2026 Jul 20. doi: 10.1038/s41409-026-02988.
    

    >> Share

    
    
18. PIERRI F, Bagnasco F, Saglio F, Fagioli F, et al
    Early inflammatory complications after haploidentical hematopoietic stem cell transplantation with post transplant cyclophosphamide for acute leukemia: a pediatric multicenter experience.
    Bone Marrow Transplant. 2026 Jul 18. doi: 10.1038/s41409-026-02976.
    

    >> Share

    
    
19. MAFFINI E, Ngoya M, Houhou M, Benakli M, et al
    Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blo
    Bone Marrow Transplant. 2026 Jul 17. doi: 10.1038/s41409-026-02991.
    

    >> Share

    
    
20. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.
    Bone Marrow Transplant. 2026 Jul 16. doi: 10.1038/s41409-026-02975.
    

    >> Share

    
    
21. NAGLER A, Esteve J, Galimard JE, Wu D, et al
    Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.
    Bone Marrow Transplant. 2026 Jul 13. doi: 10.1038/s41409-026-02970.
    

    >> Share

    
    
22. LUSSANA F, Rizzuto G, Piciocchi A, Oldani E, et al
    Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.
    Bone Marrow Transplant. 2026 Jul 8. doi: 10.1038/s41409-026-02966.
    

    >> Share

    
    
23. SWOBODA R, Labopin M, Kroger N, Stelljes M, et al
    Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.
    Bone Marrow Transplant. 2026 Jul 8. doi: 10.1038/s41409-026-02932.
    

    >> Share

    
    
24. SPYRIDONIDIS A, Ferhat AT, Galimard JE, Schroeder T, et al
    A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.
    Bone Marrow Transplant. 2026 Jul 2. doi: 10.1038/s41409-026-02950.
    

    >> Share

    
    
25. WANG M, Zhang G, Guo W, Zhang H, et al
    CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML.
    Bone Marrow Transplant. 2026;61:873-882.
    

    >> Share

    
    
26. SILVA J, Galimard JE, Dalle JH, Locatelli F, et al
    The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.
    Bone Marrow Transplant. 2026;61:891-898.
    

    >> Share

    
    June 2026
27. KAYSER S, Nagler A, Ferhat AT, Sanz J, et al
    T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/E
    Bone Marrow Transplant. 2026 Jun 27. doi: 10.1038/s41409-026-02951.
    

    >> Share

    
    
28. GAO WH, Wang CR, Wang LN, Wan M, et al
    Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study.
    Bone Marrow Transplant. 2026 Jun 25. doi: 10.1038/s41409-026-02944.
    

    >> Share

    
    
29. AVENOSO D, Radici V, Leoni A, Skert C, et al
    A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first compl
    Bone Marrow Transplant. 2026 Jun 24. doi: 10.1038/s41409-026-02937.
    

    >> Share

    
    
30. KANELLOPOULOS A, Labopin M, Spyridonidis A, Nikolousis E, et al
    Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged >/=65: a study from the ALWP of EBMT.
    Bone Marrow Transplant. 2026 Jun 21. doi: 10.1038/s41409-026-02935.
    

    >> Share

    
    
31. WU C, Xue L, Wu M, Li S, et al
    Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study.
    Bone Marrow Transplant. 2026 Jun 4. doi: 10.1038/s41409-026-02929.
    

    >> Share

    
    
32. BARBULLUSHI K, Gagelmann N, Rathje K, Badbaran A, et al
    Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.
    Bone Marrow Transplant. 2026;61:740-746.
    

    >> Share

    
    
33. MAAS-BAUER K, Meyer T, Yucel M, Garofalaki M, et al
    Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2026;61:677-684.
    

    >> Share

    
    May 2026
34. PAVIGLIANITI A, Ngoya M, Peffault de la Tour R, Schroeder T, et al
    Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMT.
    Bone Marrow Transplant. 2026 May 27. doi: 10.1038/s41409-026-02920.
    

    >> Share

    
    
35. WANG M, Luo J, Blaise D, Devillier R, et al
    Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.
    Bone Marrow Transplant. 2026 May 8. doi: 10.1038/s41409-026-02872.
    

    >> Share

    
    
36. COLMENARES R, Barragan E, Rodriguez-Veiga R, Torres-Minana L, et al
    Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.
    Bone Marrow Transplant. 2026 May 7. doi: 10.1038/s41409-026-02871.
    

    >> Share

    
    
37. STYCZYNSKI J, Tridello G, Verheggen I, Knelange N, et al
    Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective stu
    Bone Marrow Transplant. 2026 May 4. doi: 10.1038/s41409-026-02898.
    

    >> Share

    
    April 2026
38. ANDREOZZI F, Galimard JE, Maertens J, Aljurf M, et al
    Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP).
    Bone Marrow Transplant. 2026 Apr 22. doi: 10.1038/s41409-026-02857.
    

    >> Share

    
    
39. JESTIN M, Maury S, Huynh A, Forcade E, et al
    Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.
    Bone Marrow Transplant. 2026 Apr 16. doi: 10.1038/s41409-026-02837.
    

    >> Share

    
    
40. FOURMONT AM, Beauvais D, Balsat M, Maertens J, et al
    Alternative versus matched unrelated donor in adolescents and young adults transplanted for acute myeloid leukemia in first complete remission: A report from the SFGM-TC.
    Bone Marrow Transplant. 2026 Apr 13. doi: 10.1038/s41409-026-02853.
    

    >> Share

    
    
41. KANELLOPOULOS A, Koster L, de Lavallade H, Orti G, et al
    Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2026 Apr 10. doi: 10.1038/s41409-026-02862.
    

    >> Share

    
    
42. ALONSO-SALADRIGUES A, Esperanza-Cebollada E, Vicente-Garces C, Perez-Jaume S, et al
    Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy.
    Bone Marrow Transplant. 2026 Apr 4. doi: 10.1038/s41409-026-02838.
    

    >> Share

    
    March 2026
43. NAGLER A, Swoboda R, Ferhat AT, Blaise D, et al
    Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.
    Bone Marrow Transplant. 2026 Mar 25. doi: 10.1038/s41409-026-02823.
    

    >> Share

    
    
44. TAUVERON-JALENQUES U, Aspas Requena G, Gross Z, Tavernier E, et al
    Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.
    Bone Marrow Transplant. 2026 Mar 24. doi: 10.1038/s41409-026-02834.
    

    >> Share

    
    
45. SZMIT Z, Lucchini G, Bertaina A, Galimard JE, et al
    Impact of acute GvHD severity on survival and disease relapse in pediatric patients undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia: an analysis based on the EBMT-PDWP registry.
    Bone Marrow Transplant. 2026 Mar 19. doi: 10.1038/s41409-026-02797.
    

    >> Share

    
    
46. WU N, Kong J, Lv M, Mo XD, et al
    Donor age >/=50 years combined with donor-CI >/=3 identifies a high-risk cohort for adverse outcomes after allogeneic hematopoietic stem cell transplantation in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2026 Mar 18. doi: 10.1038/s41409-026-02844.
    

    >> Share

    
    
47. LEE JH, Ahn J, Kwag D, Min GJ, et al
    Relapse patterns focusing on central nervous system involvement after allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2026 Mar 14. doi: 10.1038/s41409-026-02807.
    

    >> Share

    
    
48. VON ASMUTH EGJ, Halkes CJM, Versluis J, Eikema DA, et al
    An extraction pipeline for analysis of hematopoietic stem cell transplantation data.
    Bone Marrow Transplant. 2026 Mar 10. doi: 10.1038/s41409-026-02818.
    

    >> Share

    
    
49. BUG G, Labopin M, Byrne JL, Mielke S, et al
    Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first
    Bone Marrow Transplant. 2026 Mar 6. doi: 10.1038/s41409-026-02805.
    

    >> Share

    
    
50. ABOU DALLE I, Galimard JE, Poire X, Sanz J, et al
    The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.
    Bone Marrow Transplant. 2026;61:326-332.
    

    >> Share

    
    February 2026
51. NAVARRO V, Iacoboni G, Camarillas S, Carpio C, et al
    CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2026 Feb 14. doi: 10.1038/s41409-026-02803.
    

    >> Share

    
    
52. VYDRA J, Ferhat AT, Kroger N, Gedde-Dahl T, et al
    Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrosp
    Bone Marrow Transplant. 2026;61:206-210.
    

    >> Share

    
    January 2026
53. LOPEZ-PEREIRA P, Bazarbachi A, Marcais A, Ngoya M, et al
    Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.
    Bone Marrow Transplant. 2026 Jan 3. doi: 10.1038/s41409-025-02783.
    

    >> Share

    
    
54. SALHOTRA A, Yang D, Al Malki MM, Mokhtari S, et al
    Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.
    Bone Marrow Transplant. 2026;61:82-91.
    

    >> Share

    
    December 2025
55. WETHMAR K, Edinger M, Schafer-Eckart K, Stelljes M, et al
    Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2025 Dec 6. doi: 10.1038/s41409-025-02762.
    

    >> Share

    
    
56. BAZARBACHI A, Galimard JE, Abou Dalle I, Labopin M, et al
    Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.
    Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02770.
    

    >> Share

    
    
57. BERTAINA A, Maffeis M, Lucchini G, Galimard JE, et al
    Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PD
    Bone Marrow Transplant. 2025 Dec 1. doi: 10.1038/s41409-025-02748.
    

    >> Share

    
    
58. DI MAJO BE, Abouqateb M, Galimard JE, Dalissier A, et al
    Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.
    Bone Marrow Transplant. 2025;60:1635-1641.
    

    >> Share

    
    
59. JULLIEN M, Brissot E, Daguindau E, Loschi M, et al
    Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
    Bone Marrow Transplant. 2025;60:1592-1600.
    

    >> Share

    
    November 2025
60. VILLALBA M, Ferhat AT, Gedde-Dahl T, Socie G, et al
    Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2025 Nov 29. doi: 10.1038/s41409-025-02751.
    

    >> Share

    
    
61. SANZ J, Ferhat AT, Raiola AM, Blaise D, et al
    Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2025 Nov 25. doi: 10.1038/s41409-025-02763.
    

    >> Share

    
    
62. AL-ALI RW, Gui G, Ravindra N, Andrew G, et al
    Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Nov 24. doi: 10.1038/s41409-025-02757.
    

    >> Share

    
    
63. BARBULLUSHI K, Labopin M, Kroger N, Finke J, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.
    Bone Marrow Transplant. 2025 Nov 21. doi: 10.1038/s41409-025-02740.
    

    >> Share

    
    October 2025
64. WILLASCH AM, Horgan C, Peters C, Balduzzi A, et al
    Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP.
    Bone Marrow Transplant. 2025 Oct 28. doi: 10.1038/s41409-025-02734.
    

    >> Share

    
    
65. NAGLER A, Galimard JE, Kayser S, Kulagin A, et al
    Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2025 Oct 18. doi: 10.1038/s41409-025-02726.
    

    >> Share

    
    
66. NAGLER A, Esteve J, Galimard JE, Sanz J, et al
    Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
    Bone Marrow Transplant. 2025 Oct 16. doi: 10.1038/s41409-025-02727.
    

    >> Share

    
    
67. YANADA M, Yamasaki S, Mizuno S, Sugita J, et al
    Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Oct 5. doi: 10.1038/s41409-025-02729.
    

    >> Share

    
    
68. MONTORO J, Ferhat AT, Dhedin N, Yakoub-Agha I, et al
    Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT.
    Bone Marrow Transplant. 2025;60:1309-1315.
    

    >> Share

    
    September 2025
69. MORSINK LM, Keijzer K, Hazenberg CLE, Choi G, et al
    Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD.
    Bone Marrow Transplant. 2025 Sep 19. doi: 10.1038/s41409-025-02716.
    

    >> Share

    
    
70. RU Y, Chen J, Ferhat AT, Einsele H, et al
    Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society f
    Bone Marrow Transplant. 2025 Sep 15. doi: 10.1038/s41409-025-02708.
    

    >> Share

    
    
71. DACHY G, Labopin M, Socie G, Castilla-Llorente C, et al
    Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML.
    Bone Marrow Transplant. 2025;60:1258-1264.
    

    >> Share

    
    August 2025
72. O'CONNOR TE, Lin C, Roloff GW, Zhang A, et al
    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02693.
    

    >> Share

    
    
73. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699.
    

    >> Share

    
    
74. CHAUVET P, Saade C, Demaret J, Beauvais D, et al
    Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.
    Bone Marrow Transplant. 2025 Aug 21. doi: 10.1038/s41409-025-02700.
    

    >> Share

    
    
75. CHEN H, Xu LP, Zhang XH, Wang Y, et al
    Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Bone Marrow Transplant. 2025 Aug 18. doi: 10.1038/s41409-025-02698.
    

    >> Share

    
    July 2025
76. MORALES D, Loth G, Colturato VAR, Tavares RB, et al
    Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study.
    Bone Marrow Transplant. 2025 Jul 24. doi: 10.1038/s41409-025-02676.
    

    >> Share

    
    
77. GUO LP, Hu LJ, Mo XD, Sun YQ, et al
    Characteristics and prognosis of central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with leukemia.
    Bone Marrow Transplant. 2025 Jul 17. doi: 10.1038/s41409-025-02673.
    

    >> Share

    
    
78. GIEBEL S, Labopin M, Swoboda R, Blaise D, et al
    Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2025 Jul 16. doi: 10.1038/s41409-025-02667.
    

    >> Share

    
    June 2025
79. KWAG D, Yoon JH, Min GJ, Park SS, et al
    Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents.
    Bone Marrow Transplant. 2025 Jun 17. doi: 10.1038/s41409-025-02639.
    

    >> Share

    
    
80. TERAMOTO M, Shimomura Y, Hosoi H, Yanada M, et al
    Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Jun 9. doi: 10.1038/s41409-025-02640.
    

    >> Share

    
    
81. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.
    Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02632.
    

    >> Share

    
    
82. KARAKUS A, Toptas T, Dal MS, Durdu A, et al
    Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias.
    Bone Marrow Transplant. 2025;60:864-872.
    

    >> Share

    
    
83. LI L, Zhu L, Xiong M, Chen Z, et al
    Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older.
    Bone Marrow Transplant. 2025;60:773-778.
    

    >> Share

    
    May 2025
84. NAGLER A, Ferhat AT, Kayser S, Eder M, et al
    Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT.
    Bone Marrow Transplant. 2025 May 29. doi: 10.1038/s41409-025-02620.
    

    >> Share

    
    
85. MOUKALLED N, Ferhat AT, Bazarbachi A, Blaise D, et al
    Improved outcomes over time in patients aged >/=60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.
    Bone Marrow Transplant. 2025 May 28. doi: 10.1038/s41409-025-02630.
    

    >> Share

    
    
86. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
    Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
    

    >> Share

    
    
87. KRAKOW EF, Lee N, Jenkins I, Sala-Torra O, et al
    A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing.
    Bone Marrow Transplant. 2025 May 16. doi: 10.1038/s41409-025-02602.
    

    >> Share

    
    
88. BATTIPAGLIA G, Labopin M, Kulagin A, Versluis J, et al
    Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute mye
    Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02610.
    

    >> Share

    
    April 2025
89. PERMINOVA M, Shelikhova L, Klimentova M, Skvortsova Y, et al
    Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial.
    Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02566.
    

    >> Share

    
    
90. TARANTINO S, Labopin M, Zeiser R, Stelljes M, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596.
    

    >> Share

    
    
91. BERGLAND BS, Remberger M, Tjonnfjord GE, Vo CD, et al
    Should a young matched unrelated donor be preferred over an older matched related donor in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02579.
    

    >> Share

    
    
92. GILLE AS, Lenez L, Vanhaesebrouck A, Rivet-Danon D, et al
    First-line chemotherapies administered before hematopoietic cell transplantation in children with acute leukemia: effect on the spermatogonial pool.
    Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02547.
    

    >> Share

    
    
93. ABOU DALLE I, Labopin M, Khvedelidze I, Baron F, et al
    Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party.
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02576.
    

    >> Share

    
    
94. SENAPATI J, Garcia-Manero G, DiNardo CD, Deshmukh I, et al
    Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590.
    

    >> Share

    
    
95. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    

    >> Share

    
    
96. LIU J, Li Y, Zhu F, Lv B, et al
    Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia.
    Bone Marrow Transplant. 2025 Apr 7. doi: 10.1038/s41409-025-02578.
    

    >> Share

    
    
97. SHIMIZU T, Arai Y, Kondo T, Yano S, et al
    Improved post-transplant outcomes for elderly acute myeloid leukemia patients conditioned with FLU/BU4 rather than conventional MAC regimens.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02573.
    

    >> Share

    
    
98. YANADA M, Yamasaki S, Hosoi H, Mizuno S, et al
    Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02585.
    

    >> Share

    
    
99. SPYRIDONIDIS A, Labopin M, Savani BP, Kulagin A, et al
    The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2025;60:499-506.
    

    >> Share

    
    
100. VO PT, Sandmaier BM, Othus M, Ali N, et al
     Relationship between age, conditioning intensity, and outcome after allografting in adults age >/=60 years with AML.
     Bone Marrow Transplant. 2025;60:482-490.
     

     >> Share

     
     March 2025
101. STORCK TN, Morsink LM, Biswana A, Hazenberg CLE, et al
     Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients.
     Bone Marrow Transplant. 2025 Mar 19. doi: 10.1038/s41409-025-02552.
     

     >> Share

     
     
102. CALVO C, Mornet C, Storey C, Halfon-Domenech C, et al
     Adult height and growth hormone therapy in childhood acute lymphoblastic leukemia survivors treated with total body irradiation and hematopoietic stem cell transplantation before puberty.
     Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02532.
     

     >> Share

     
     
103. ZHOU JY, Chen YX, Yuan HL, Xu YJ, et al
     A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.
     Bone Marrow Transplant. 2025;60:310-318.
     

     >> Share

     
     February 2025
104. GANG M, Othus M, Sandmaier BM, Davis C, et al
     Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission.
     Bone Marrow Transplant. 2025 Feb 17. doi: 10.1038/s41409-025-02533.
     

     >> Share

     
     
105. SANZ J, Labopin M, Versluis J, Blaise D, et al
     Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.
     Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02527.
     

     >> Share

     
     
106. ZHOU J, Wang F, Yang S, Zhang Y, et al
     Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
     Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
     

     >> Share

     
     
107. SHAFFER BC, Kebriaei P, de Lima M, Jimenez Jimenez AM, et al
     Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.
     Bone Marrow Transplant. 2025;60:128-134.
     

     >> Share

     
     
108. GOMEZ-ARTEAGA A, Chokr N, Auletta JJ
     Precision medicine results from equitable representation.
     Bone Marrow Transplant. 2025;60:122-127.
     

     >> Share

     
     January 2025
109. NEUPANE B, Ventura K, Parr K, Lee JR, et al
     Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia neoantigens elicit immune responses in transplant recipients?
     Bone Marrow Transplant. 2025 Jan 29. doi: 10.1038/s41409-025-02515.
     

     >> Share

     
     
110. OSHIMA S, Arai Y, Kondo T, Yano S, et al
     Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.
     Bone Marrow Transplant. 2025 Jan 21. doi: 10.1038/s41409-025-02508.
     

     >> Share

     
     
111. BLACKMON AL, Grunwald MR
     Editorial: Molecular MRD testing in patients with acute myeloid leukemia.
     Bone Marrow Transplant. 2025 Jan 11. doi: 10.1038/s41409-024-02493.
     

     >> Share

     
     December 2024
112. YU F, Niu J, Yang J, Hou J, et al
     Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
     Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
     

     >> Share

     
     
113. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
     Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Part
     Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499.
     

     >> Share

     
     
114. BLACKMON A, Afkhami M, Yang D, Mokhtari S, et al
     Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
     Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491.
     

     >> Share

     
     
115. WANG MM, Huang SM, Huang YH, Zhang J, et al
     Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.
     Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02495.
     

     >> Share

     
     
116. SUN J, Zhang YC, Wei J, Xu YJ, et al
     Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.
     Bone Marrow Transplant. 2024 Dec 2. doi: 10.1038/s41409-024-02485.
     

     >> Share

     
     
117. SALAS MQ, Cascos E, Lopez-Garcia A, Perez-Lopez E, et al
     Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC.
     Bone Marrow Transplant. 2024;59:1694-1703.
     

     >> Share

     
     
118. BRUNE M, Kiss T, Anderson H, Nicklasson M, et al
     Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.
     Bone Marrow Transplant. 2024;59:1676-1682.
     

     >> Share

     
     November 2024
119. MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al
     Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
     Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473.
     

     >> Share

     
     
120. LI SQ, Yu CZ, Xu LP, Wang Y, et al
     Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
     Bone Marrow Transplant. 2024 Nov 16. doi: 10.1038/s41409-024-02466.
     

     >> Share

     
     
121. CHRISTOPHER MR, Nawas MT, Reagan JL
     Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Nov 13. doi: 10.1038/s41409-024-02465.
     

     >> Share

     
     
122. GUI G, Ravindra N, Hegde PS, Andrew G, et al
     Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02447.
     

     >> Share

     
     
123. MA R, Liao Y, Zhang XH, Xu LP, et al
     Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02457.
     

     >> Share

     
     
124. OTOUKESH S, Yang D, Mokhtari S, Pourhassan H, et al
     Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings.
     Bone Marrow Transplant. 2024;59:1542-1551.
     

     >> Share

     
     October 2024
125. ELGHAWY O, Deshpande S, Sussman J, Garfall A, et al
     Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
     Bone Marrow Transplant. 2024 Oct 30. doi: 10.1038/s41409-024-02455.
     

     >> Share

     
     
126. GUI G, Ravindra N, Hegde PS, Andrew G, et al
     Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02449.
     

     >> Share

     
     
127. HEGDE PS, Andrew G, Gui G, Ravindra N, et al
     Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02444.
     

     >> Share

     
     
128. NGO D, Blackmon A, Al Malki MM
     Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.
     Bone Marrow Transplant. 2024 Oct 8. doi: 10.1038/s41409-024-02425.
     

     >> Share

     
     August 2024
129. OTHUS M, Baccon D, Ali N, Rodriguez-Arboli E, et al
     Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Aug 29. doi: 10.1038/s41409-024-02407.
     

     >> Share

     
     
130. ZHANG H, Guo W, Wang J, Lu N, et al
     Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Aug 27. doi: 10.1038/s41409-024-02402.
     

     >> Share

     
     
131. SAKAGUCHI H, Taga T, Ishida H, Hama A, et al
     Salvage hematopoietic cell transplantation for children with acute myeloid leukemia relapsed after first transplantation: a Japanese national registry study.
     Bone Marrow Transplant. 2024 Aug 22. doi: 10.1038/s41409-024-02396.
     

     >> Share

     
     
132. NAGLER A, Labopin M, Salmenniemi U, Wu D, et al
     Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT.
     Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02379.
     

     >> Share

     
     
133. NAGLER A, Labopin M, Swoboda R, Blaise D, et al
     Young (<35 years) haploidentical versus old (>/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on
     Bone Marrow Transplant. 2024 Aug 18. doi: 10.1038/s41409-024-02400.
     

     >> Share

     
     
134. MOHTY R, Bazarbachi AH, Labopin M, Esteve J, et al
     Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT.
     Bone Marrow Transplant. 2024 Aug 14. doi: 10.1038/s41409-024-02384.
     

     >> Share

     
     
135. GALLI E, Corrente A, Chiusolo P, Sica S, et al
     CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL).
     Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02386.
     

     >> Share

     
     
136. AL HAMED R, Labopin M, Wu D, Gedde-Dahl T, et al
     Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
     Bone Marrow Transplant. 2024 Aug 2. doi: 10.1038/s41409-024-02373.
     

     >> Share

     
     July 2024
137. GANZEL C, Wang Y, Roopcharan K, Sun Z, et al
     Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
     Bone Marrow Transplant. 2024 Jul 18. doi: 10.1038/s41409-024-02337.
     

     >> Share

     
     
138. AHN J, Yoon JH, Kwag D, Min GJ, et al
     Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.
     Bone Marrow Transplant. 2024 Jul 12. doi: 10.1038/s41409-024-02363.
     

     >> Share

     
     
139. BUG G, Labopin M, Kulagin A, Blaise D, et al
     Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT).
     Bone Marrow Transplant. 2024 Jul 3. doi: 10.1038/s41409-024-02331.
     

     >> Share

     
     June 2024
140. ZHU J, Xu M, Ye Y, Ru Y, et al
     Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study.
     Bone Marrow Transplant. 2024 Jun 19. doi: 10.1038/s41409-024-02335.
     

     >> Share

     
     
141. STEINER N, Massoud R, Klyuchnikov E, Gagelmann N, et al
     Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2024 Jun 14. doi: 10.1038/s41409-024-02328.
     

     >> Share

     
     
142. ORCHARD K, Langford J, Guy M, Lewis G, et al
     Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2024 Jun 12. doi: 10.1038/s41409-024-02317.
     

     >> Share

     
     
143. EL CHEIKH J, Ngoya M, Galimard JE, Remenyi P, et al
     Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
     Bone Marrow Transplant. 2024 Jun 4. doi: 10.1038/s41409-024-02300.
     

     >> Share

     
     
144. KUROSAWA S, Shimomura Y, Ishiyama K, Fuse K, et al
     Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study.
     Bone Marrow Transplant. 2024;59:742-750.
     

     >> Share

     
     May 2024
145. GANZEL C, Yating W, Roopcharan K, Sun Z, et al
     Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
     Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02308.
     

     >> Share

     
     
146. TOLOSA-RIDAO C, Suarez-Lledo M, Jimenez-Vicente C, Cortes-Bullich A, et al
     Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia.
     Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02310.
     

     >> Share

     
     
147. HU X, Wang Z, Qin Y, Xu J, et al
     Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion.
     Bone Marrow Transplant. 2024 May 20. doi: 10.1038/s41409-024-02306.
     

     >> Share

     
     
148. MORA E, Montoro J, Balaguer A, Rovira M, et al
     Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
     Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298.
     

     >> Share

     
     
149. SINANIDIS I, Hochman MJ, Tsai HL, Randall MP, et al
     Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
     Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299.
     

     >> Share

     
     
150. BERNING P, Kolloch L, Reicherts C, Call S, et al
     Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
     Bone Marrow Transplant. 2024 May 3. doi: 10.1038/s41409-024-02295.
     

     >> Share

     
     
151. BEELEN DW, Iacobelli S, Koster L, Eikema DJ, et al
     Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
     Bone Marrow Transplant. 2024;59:670-679.
     

     >> Share

     
     April 2024
152. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
     Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
     Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
     

     >> Share

     
     
153. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
     Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
     Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
     

     >> Share

     
     
154. SHEN Y, Liu M, Shen D, Chu M, et al
     Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
     Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
     

     >> Share

     
     
155. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
     Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
     Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
     

     >> Share

     
     
156. BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al
     EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
     Bone Marrow Transplant. 2024;59:558-560.
     

     >> Share

     
     March 2024
157. MAFFINI E, Labopin M, Kroger N, Finke J, et al
     Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
     Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275.
     

     >> Share

     
     
158. KOO RM, Wong E, Davis JE, Perera T, et al
     A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
     Bone Marrow Transplant. 2024 Mar 27. doi: 10.1038/s41409-023-02195.
     

     >> Share

     
     
159. SHANG Q, Bai L, Cheng Y, Suo P, et al
     Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.
     Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214.
     

     >> Share

     
     
160. PARK S, Bang SY, Kwag D, Lee JH, et al
     Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
     Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
     

     >> Share

     
     February 2024
161. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
     A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
     Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
     

     >> Share

     
     
162. YANADA M, Yano S, Kuwatsuka Y, Kawamura K, et al
     The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02222.
     

     >> Share

     
     
163. SPYRIDONIDIS A, Labopin M, Gedde-Dahl T, Ganser A, et al
     Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2024;59:217-223.
     

     >> Share

     
     January 2024
164. XIAO M, Zhou J, Zhu X, He Y, et al
     A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211.
     

     >> Share

     
     
165. CHEN W, Shi J, Luo Y, Yu J, et al
     Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
     Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
     

     >> Share

     
     
166. ALBINGER N, Muller S, Kostyra J, Kuska J, et al
     Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Jan 22. doi: 10.1038/s41409-023-02180.
     

     >> Share

     
     
167. SHARMA A, Galimard JE, Pryce A, Bhoopalan SV, et al
     Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
     Bone Marrow Transplant. 2024 Jan 15. doi: 10.1038/s41409-024-02197.
     

     >> Share

     
     
168. VELARDI A, Mancusi A, Ruggeri L, Pierini A, et al
     How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia.
     Bone Marrow Transplant. 2024 Jan 11. doi: 10.1038/s41409-024-02199.
     

     >> Share

     
     
169. ARCURI LJ
     Re: Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
     Bone Marrow Transplant. 2024 Jan 10. doi: 10.1038/s41409-023-02186.
     

     >> Share

     
     
170. SADOWSKA-KLASA A, Zaucha JM, Labopin M, Bourhis JH, et al
     Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.
     Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02192.
     

     >> Share

     
     
171. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
     Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
     Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
     

     >> Share

     
     
172. RAVINDRA N, Dillon LW, Gui G, Smith M, et al
     Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
     Bone Marrow Transplant. 2024 Jan 5. doi: 10.1038/s41409-023-02189.
     

     >> Share

     
     December 2023
173. ZHANG X, Pang Y, Wei C, Liang D, et al
     Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
     Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
     

     >> Share

     
     
174. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
     Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
     Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
     

     >> Share

     
     
175. POIRE X, Labopin M, Polge E, Ganser A, et al
     Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.
     Bone Marrow Transplant. 2023 Dec 13. doi: 10.1038/s41409-023-02167.
     

     >> Share

     
     
176. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
     Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT
     Bone Marrow Transplant. 2023 Dec 2. doi: 10.1038/s41409-023-02150.
     

     >> Share

     
     November 2023
177. CAO LQ, Huo WX, Zhang XH, Xu LP, et al
     Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.
     Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117.
     

     >> Share

     
     
178. HARBI S, Brac de la Perriere L, Bouchacourt B, Garciaz S, et al
     Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
     Bone Marrow Transplant. 2023 Nov 3. doi: 10.1038/s41409-023-02134.
     

     >> Share

     
     October 2023
179. YANG L, Lai X, Yang T, Lu Y, et al
     Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
     Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02137.
     

     >> Share

     
     
180. HUANG J, Feng B, Cheng Y, Xu L, et al
     Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study.
     Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02141.
     

     >> Share

     
     
181. CANCIO M, Troullioud Lucas AG, Bierings M, Klein E, et al
     Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
     Bone Marrow Transplant. 2023 Oct 17. doi: 10.1038/s41409-023-02121.
     

     >> Share

     
     
182. CHO C, Devlin S, Maloy M, Horowitz MM, et al
     Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.
     Bone Marrow Transplant. 2023;58:1089-1095.
     

     >> Share

     
     
183. RIEGER MJ, Stolz SM, Muller AM, Schwotzer R, et al
     Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.
     Bone Marrow Transplant. 2023;58:1121-1129.
     

     >> Share

     
     
184. YANADA M, Shimomura Y, Mizuno S, Matsuda K, et al
     External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia.
     Bone Marrow Transplant. 2023;58:1096-1103.
     

     >> Share

     
     
185. GAVRIILAKI E, Sakellari I, Labopin M, Bornhauser M, et al
     Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Ac
     Bone Marrow Transplant. 2023;58:1084-1088.
     

     >> Share

     
     September 2023
186. SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al
     T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML.
     Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113.
     

     >> Share

     
     
187. CAO Y, Zhang C, Zhao X, Huang J, et al
     Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China.
     Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02106.
     

     >> Share

     
     
188. HARADA N, Okamura H, Makuuchi Y, Kuno M, et al
     Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia.
     Bone Marrow Transplant. 2023 Sep 15. doi: 10.1038/s41409-023-02108.
     

     >> Share

     
     
189. NAGLER A, Labopin M, Kroger N, Schroeder T, et al
     The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
     Bone Marrow Transplant. 2023 Sep 2. doi: 10.1038/s41409-023-02095.
     

     >> Share

     
     
190. JENG MY, Kong D, Rajalingam R, Lin RJ, et al
     Lack of disease control remains a major barrier to transplant for older patients with AML.
     Bone Marrow Transplant. 2023;58:1054-1056.
     

     >> Share

     
     August 2023
191. REY G, Daguenet E, Bonjean P, Devillier R, et al
     Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
     Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02082.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share